Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 25 Sep 2025

Prognostic impact of miR-17-5p and miR-20a-5p in NSCLC diverge in subgroups according to lymph node status

in Cancer Molecular Targets and Therapeutics

Dagny Førde
Thomas Kilvær
Mona Irene Pedersen
Ana Paola Lombardi
Irene D’arsiè
Erna-Elise Paulsen
Lill-Tove Rasmussen Busund
Mehrdad Rakaee
Tom Dønnem
Sigve Andersen

Frontiers in Oncology

doi 10.3389/fonc.2025.1606933

592 views

Original Research

Accepted on 24 Sep 2025

Integrated machine learning-based establishment of a prognostic model in multicenter cohorts for acute myeloid leukemia

in Cancer Molecular Targets and Therapeutics

Yan Lin
Huasong Yu
Xiaoyi Xu
Mingcheng Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1649594

215 views

Correction

Published on 24 Sep 2025

Correction: Application and development of Organ-on-a-Chip technology in cancer therapy

in Cancer Molecular Targets and Therapeutics

Ling xiao Wang
Shu ling Liu
Ning Wu

Frontiers in Oncology

doi 10.3389/fonc.2025.1703677

936 views

Correction

Published on 23 Sep 2025

Correction: Editorial: Current status and recent advances in preclinical models for rare cancers

in Cancer Molecular Targets and Therapeutics

Ewa Krawczyk
Luciane R. Cavalli
Joanna Kitlinska

Frontiers in Oncology

doi 10.3389/fonc.2025.1697286

629 views

Original Research

Published on 23 Sep 2025

Mechanistic studies of miR-582-3p targeting of PTPRCAP affecting lung adenocarcinoma via the Wnt/β-catenin pathway

in Cancer Molecular Targets and Therapeutics

Yuting Yang
Song Zhao
Xiaoli Han
Pengfei Guo
Baoshan Zhao
Zongying Liang

Frontiers in Oncology

doi 10.3389/fonc.2025.1652176

751 views

Original Research

Accepted on 22 Sep 2025

Construction of a Prognostic Model for Colorectal Cancer Liver Metastasis Based on Single-Cell Transcriptomics and Regulation of the MIF Pathway

in Cancer Molecular Targets and Therapeutics

Jianqiang Cao
Zhaobin He
HuiJie Gao
Yongzhe Yu
Shengbiao Yang
Xiqiang Wang
Jun Niu
Cheng Peng

Frontiers in Oncology

doi 10.3389/fonc.2025.1588514

328 views

Original Research

Accepted on 22 Sep 2025

Downregulation of SALL1 and Its Association with Poor Prognosis and the Immune Cell Landscape in Clear Cell Renal Cell Carcinoma

in Cancer Molecular Targets and Therapeutics

GenYi Qu
Shao-Hao Chen
Meng-Xin Liu
Yi-Jie Wang
Zhao-Hui Long
Ning Xu
Xue Yi Xue

Frontiers in Oncology

doi 10.3389/fonc.2025.1624651

246 views

Original Research

Accepted on 22 Sep 2025

CLIC6's role in cancer: from broad analysis to breast cancer validation

in Cancer Molecular Targets and Therapeutics

Junyi Wang
Yiyang Wang
Haotian Ma
Yongxiang Li
Jiayue Hou
Jiaqi Li
Dilimulati Ismtula
Chenming Guo

Frontiers in Oncology

doi 10.3389/fonc.2025.1667589

135 views

Review

Accepted on 22 Sep 2025

Potential Immunogenic Modulation of Hypo-fractionated Radiotherapy at Optimal Schedules and the Subsequent Vaccine-Like Effect of Local Irradiation - A Systematic Review

in Cancer Molecular Targets and Therapeutics

Jagtar Singh
Martin Ashdown
Siddhartha Baxi

Frontiers in Oncology

doi 10.3389/fonc.2025.1546875

104 views

Case Report

Accepted on 19 Sep 2025

Pathologic complete response of advanced hepatoid adenocarcinoma of the stomach following immuno-chemotherapy and conversion surgery: A rare case report and review of the literature

in Cancer Molecular Targets and Therapeutics

Yaoqi Li
You Wang
Tao Yu
Dong Wang
Hong Ma
Jichun Ma
Da Mingxu

Frontiers in Oncology

doi 10.3389/fonc.2025.1648766

448 views

Perspective

Published on 17 Sep 2025

Role and prognostic value of oncostatin M and its receptor OSMR in acute myeloid leukemia, myeloproliferative neoplasms and non-hematological malignancies

in Cancer Molecular Targets and Therapeutics

Jean-Pierre Lévesque
Kavita Bisht
Kylie A. Alexander
Ingrid G. Winkler

Frontiers in Oncology

doi 10.3389/fonc.2025.1636570

776 views

Review

Accepted on 16 Sep 2025

Comparing the risk of cardiovascular disease between degarelix and gonadotropin-releasing hormone agonists：a systematic review and meta-analysis

in Cancer Molecular Targets and Therapeutics

Wencong Liu
Zhenyu Liu
Liangdong Song
Zhu Huixuan
Yu Luo
Jindong Zhang
Shuai Su
Delin Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1523794

678 views

Review

Accepted on 12 Sep 2025

PROTAC: A Revolutionary Technology Propelling Small Molecule Drugs into the Next Golden Age

in Cancer Molecular Targets and Therapeutics

Jiale Cai
Chen Chen
Jiayue Wang
Xinmeng Zhang
Yuqiu Cui
Qunshan Zhu
Haibo Sun

Frontiers in Oncology

doi 10.3389/fonc.2025.1676414

773 views

Original Research

Published on 10 Sep 2025

Prognostic value and molecular mechanism of photodynamic therapy and apoptosis related gene FGFR1 in bladder cancer

in Cancer Molecular Targets and Therapeutics

Lei Wang
Yanchun Wang
Yanqing Wang
Zhengwei Wang
Guangzhou Cheng
Zhunan Xu
Xiaoqiang Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1578695

818 views

Original Research

Published on 10 Sep 2025

Outcomes and prognostic factors of alternative treatment regimens for angioimmunoblastic T-cell lymphoma: a retrospective analysis

in Cancer Molecular Targets and Therapeutics

Jiaqin Yan
Jiebing Wang
Junhui Zhang
Xudong Zhang
Lei Zhang
Zunmin Zhu
Mingzhi Zhang

Frontiers in Oncology

doi 10.3389/fonc.2025.1585013

962 views

Original Research

Published on 10 Sep 2025

KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC

in Cancer Molecular Targets and Therapeutics

Alessandro Tubita
Sara Fancelli
Lorenzo Anela
Giulia Petroni
Enrico Caliman
Francesca Mazzoni
Federico Scolari
Brunella Napolitano
Beatrice Menicacci
Camilla Eva Comin

Frontiers in Oncology

doi 10.3389/fonc.2025.1654491

1,095 views